Javier D. L. R. C.
- Country
- Spain
- Department
- Servicio de Hematologia
Research Overview
- Safety and Pharmacokinetics of XMAB24306 with Daratumumab in Relapsed/Refractory Multiple Myeloma Patients
- Safety Evaluation of CC-93269 in Patients with Relapsed and Refractory Multiple Myeloma
- Efficacy and Safety of Etentamig and Daratumumab Versus Daratumumab and Combination Therapy in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Data & Insights
Has run more than one trial at 254 of 394 partner sites.
Specializations
Multiple Myeloma Research
This investigator specializes in the study of multiple myeloma, with particular emphasis on both newly diagnosed and relapsed/refractory cases. Their research encompasses various treatment approaches including monoclonal antibodies, immunomodulatory drugs, and targeted therapies.
- Newly Diagnosed Multiple Myeloma
- Relapsed/Refractory Multiple Myeloma
- Post-Transplant Therapy
Blood Disorders
The investigator conducts research in rare blood disorders, particularly focusing on thrombotic thrombocytopenic purpura and its immune-mediated variants. Their work includes evaluation of novel therapeutic approaches for these conditions.
- Immune-Mediated TTP
- Systemic Light Chain Amyloidosis
- Hematologic Malignancies
Therapeutic Innovations
Research activities include investigation of novel therapeutic combinations and cell-based therapies. The investigator evaluates emerging treatment modalities including gene-modified T cells and innovative drug combinations.
- Cellular Therapy
- Combination Treatments
- Maintenance Therapy
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.